

Marleen Keyaerts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7179972/publications.pdf>

Version: 2024-02-01

61
papers

2,734
citations

201385

27
h-index

182168

51
g-index

61
all docs

61
docs citations

61
times ranked

3142
citing authors

#	ARTICLE	IF	CITATIONS
1	The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 159-169.	1.9	9
2	Abstract P3-02-05: Assessment of repeatability and uptake quantification of ⁶⁸ GaNOTA-anti-HER2 sdAb PET/CT in patients with locally advanced or metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P3-02-05-P3-02-05.	0.4	0
3	Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177â€“Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1136-1148.	1.9	5
4	Computer-aided detection and segmentation of malignant melanoma lesions on whole-body ^{18}F -FDG PET/CT using an interpretable deep learning approach. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 221, 106902.	2.6	9
5	Phase I Trial of ^{131}I -GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1097-1105.	2.8	67
6	Immunogenicity Risk Profile of Nanobodies. <i>Frontiers in Immunology</i> , 2021, 12, 632687.	2.2	97
7	Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1638-1644.	2.8	26
8	Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome. <i>Current Oncology</i> , 2021, 28, 1630-1640.	0.9	4
9	⁶⁸ Ga-Labeling: Laying the Foundation for an Anti-Radiolytic Formulation for NOTA-sdAb PET Tracers. <i>Pharmaceuticals</i> , 2021, 14, 448.	1.7	3
10	Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimideâ€“Cysteine Chemistry. <i>Pharmaceuticals</i> , 2021, 14, 550.	1.7	15
11	The Prognostic Value of CD206 in Solid Malignancies: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 3422.	1.7	15
12	Lyophilization of NOTA-sdAbs: First step towards a cold diagnostic kit for ⁶⁸ Ga-labeling. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 166, 194-204.	2.0	4
13	Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 22, 172-182.	1.8	11
14	A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. <i>Cancers</i> , 2021, 13, 168.	1.7	24
15	The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Timeâ€™s a Charm. <i>International Journal of Molecular Sciences</i> , 2021, 22, 75.	1.8	87
16	Undetectable thyroglobulin makes ¹²³ I whole-body scan and stimulated thyroglobulin obsolete in follow-up care of differentiated thyroid cancer: a retrospective study. <i>Thyroid Research</i> , 2021, 14, 23.	0.7	0
17	Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer. <i>EJNMMI Research</i> , 2021, 11, 115.	1.1	5
18	Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation. <i>Biomolecules</i> , 2020, 10, 1388.	1.8	42

#	ARTICLE	IF	CITATIONS
19	18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. <i>Cancer Imaging</i> , 2020, 20, 36.	1.2	46
20	Preclinical Targeted ^{125}I - and ^{225}Ac -Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies. <i>Cancers</i> , 2020, 12, 1017.	1.7	43
21	Baseline biomarkers correlated with outcome in advanced melanoma treated with pembrolizumab monotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, e22041-e22041.	0.8	2
22	Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production. <i>Vaccines</i> , 2019, 7, 85.	2.1	17
23	Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent. <i>Cancers</i> , 2019, 11, 872.	1.7	50
24	Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior. <i>Molecular Pharmaceutics</i> , 2019, 16, 3524-3533.	2.3	42
25	Theranostics in immuno-oncology using nanobody derivatives. <i>Theranostics</i> , 2019, 9, 7772-7791.	4.6	83
26	Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. <i>Journal of Translational Medicine</i> , 2019, 17, 303.	1.8	89
27	Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use. <i>Biomolecules</i> , 2019, 9, 548.	1.8	43
28	Next-generation muscle-directed gene therapy by in silico vector design. <i>Nature Communications</i> , 2019, 10, 492.	5.8	35
29	Perforin and Granzyme B Expressed by Murine Myeloid-Derived Suppressor Cells: A Study on Their Role in Outgrowth of Cancer Cells. <i>Cancers</i> , 2019, 11, 808.	1.7	22
30	Clinical Translation of ^{68}Ga -Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic Macrophages. <i>Molecular Imaging and Biology</i> , 2019, 21, 898-906.	1.3	69
31	Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology. <i>Journal of Nuclear Medicine</i> , 2018, 59, 885-891.	2.8	101
32	Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab. <i>Annals of Oncology</i> , 2018, 29, x7.	0.6	3
33	Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy. <i>Theranostics</i> , 2018, 8, 3559-3570.	4.6	85
34	Phase I results of CAM-H2: Safety profile and tumor targeting in patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13017-e13017.	0.8	6
35	A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches. <i>Oncotarget</i> , 2018, 9, 27797-27808.	0.8	17
36	Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery. <i>Gene Therapy</i> , 2017, 24, 370-375.	2.3	11

#	ARTICLE	IF	CITATIONS
37	Adjuvant-Enhanced mRNA Vaccines. <i>Methods in Molecular Biology</i> , 2017, 1499, 179-191.	0.4	6
38	Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. <i>Oncotarget</i> , 2017, 8, 41932-41946.	0.8	95
39	Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1035-1047.	1.4	119
40	Phase I Study of ⁶⁸ Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma. <i>Journal of Nuclear Medicine</i> , 2016, 57, 27-33.	2.8	317
41	Genome-wide Computational Analysis Reveals Cardiomyocyte-specific Transcriptional Cis-regulatory Motifs That Enable Efficient Cardiac Gene Therapy. <i>Molecular Therapy</i> , 2015, 23, 43-52.	3.7	36
42	Agenesis of the pubic symphysis detected with SPECT-CT. <i>Journal of the Belgian Society of Radiology</i> , 2015, 94, 97.	0.2	0
43	Selective spleen SPECT/CT. <i>Journal of the Belgian Society of Radiology</i> , 2015, 94, 353.	0.2	0
44	Erdheim-Chester disease detected with ^{99m} Tc MDP bone SPECT/CT. <i>Journal of the Belgian Society of Radiology</i> , 2015, 95, 245.	0.2	2
45	Port-site metastasis after explorative laparoscopy for an incidental appendiceal mucinous cystadenocarcinoma detected with FDG PET/CT. <i>Journal of the Belgian Society of Radiology</i> , 2015, 96, 43.	0.2	1
46	Nanobody-based PET/CT imaging of HER2 expression in breast carcinoma: Phase I results and potential to assess tumor heterogeneity.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11600-e11600.	0.8	0
47	Synthesis, Preclinical Validation, Dosimetry, and Toxicity of ⁶⁸ Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 776-784.	2.8	173
48	Air Leaks Localized With Lung Ventilation SPECT. <i>Clinical Nuclear Medicine</i> , 2012, 37, 1182-1183.	0.7	6
49	Bioluminescence imaging: looking beyond the light. <i>Trends in Molecular Medicine</i> , 2012, 18, 164-172.	3.5	85
50	Inhibition of Firefly Luciferase by General Anesthetics: Effect on In Vitro and In Vivo Bioluminescence Imaging. <i>PLoS ONE</i> , 2012, 7, e30061.	1.1	40
51	Plasma Protein Binding of Luciferase Substrates Influences Sensitivity and Accuracy of Bioluminescence Imaging. <i>Molecular Imaging and Biology</i> , 2011, 13, 59-66.	1.3	17
52	Correlation Between Epidermal Growth Factor Receptor-Specific Nanobody Uptake and Tumor Burden: A Tool for Noninvasive Monitoring of Tumor Response to Therapy. <i>Molecular Imaging and Biology</i> , 2011, 13, 940-948.	1.3	51
53	HIV-1 Lentiviral Vector Immunogenicity Is Mediated by Toll-Like Receptor 3 (TLR3) and TLR7. <i>Journal of Virology</i> , 2010, 84, 5627-5636.	1.5	129
54	Preliminary <i>In Vivo</i> Evaluation of [¹³¹ I]-2-Iodo-D-Phenylalanine as a Potential Radionuclide Therapeutic Agent in R1M-Fluc Rhabdomyosarcoma Tumor-Bearing NuNu Mice Using Bioluminescent Imaging. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 225-231.	0.7	2

#	ARTICLE	IF	CITATIONS
55	Regional quantitative analysis of small animal myocardial sympathetic innervation and initial application in streptozotocin induced diabetes. <i>Contrast Media and Molecular Imaging</i> , 2009, 4, 174-182.	0.4	10
56	SPECT Imaging with ^{99m} Tc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression. <i>Molecular Imaging and Biology</i> , 2008, 10, 167-175.	1.3	158
57	Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of d-luciferin: effect on intensity, time kinetics and repeatability of photon emission. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 999-1007.	3.3	84
58	Comparison of the Biodistribution and Tumor Targeting of Two ^{99m} Tc-Labeled Anti-EGFR Nanobodies in Mice, Using Pinhole SPECT/Micro-CT. <i>Journal of Nuclear Medicine</i> , 2008, 49, 788-795.	2.8	194
59	Intra-individual comparison of the human biodistribution and dosimetry of the D and L isomers of 2-[¹²³ I]iodo-phenylalanine. <i>Nuclear Medicine Communications</i> , 2007, 28, 823-828.	0.5	6
60	¹²³ I-2-iodo-tyrosine, a new tumour imaging agent: human biodistribution, dosimetry and initial clinical evaluation in glioma patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 994-1002.	3.3	9
61	The role of chemotherapy in the treatment of low-grade glioma. A review of the literature. <i>Acta Neurologica Belgica</i> , 2005, 105, 137-43.	0.5	7